卡格列净对心血管保护作用的研究进展  

Research progress on cardiovascular protection of canagliflozin

作　　者：褚文欣 梁梅花[1] CHU Wen-xin;LIANG Mei-hua(Department of Endocrinology and Metabolism,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌代谢科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2023年第4期422-426,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：心血管疾病已成为糖尿病患者死亡的首要原因,单纯血糖控制对降低心血管死亡风险的作用有限。卡格列净(canagliflozin)是一种钠葡萄糖共转运蛋白(SGLT)2抑制剂,通过阻断肾脏对葡萄糖的重吸收来降低血糖水平,不依赖于胰岛素的分泌或作用,具有降糖、减重、降压等作用,还能够显著降低心血管事件风险,本文主要就卡格列净的心血管保护作用进行综述。Cardiovascular diseases have become the leading cause of death in patients with diabetes mellitus(DM).Blood glucose control alone plays a limited role in reducing the risk of cardiovascular death.Canagliflozin is a sodium glucose co-transporter 2(SGLT2) inhibitor.It can reduce blood glucose level by blocking renal reabsorption of glucose independent from insulin secretion or effect.Canagliflozin can lower blood glucose,reduce body weight and blood pressure etc.,and significantly reduce the risk of cardiovascular events.The present article mainly makes a review on cardiovascular protective effect of canagliflozin.

关 键 词：心血管疾病 糖尿病 2型 钠-葡萄糖转运体2 

分 类 号：R54[医药卫生—心血管疾病]